Galectin Offers Subgroup Approach For Struggling NASH Candidate
Executive Summary
Having failed to meet its primary endpoint in consecutive Phase II studies, Galectin hopes to move GR-MD-02 forward in NASH in patients with cirrhosis who have not developed esophageal varices.
You may also be interested in...
Galectin’s NASH Phase III Trial Will Use Surrogate Measures Of Esophageal Varices
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.
Galectin’s NASH Challenges: Paying For Phase III, Carving Market Niche
Galectin faces a dual challenge - do its planned trial well and trust that the study design will lead the galectin-3 inhibitor belapectin to a niche position in NASH.
NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs
Although guidance appears to be free of surprises, US FDA once again made a push for sponsors to adopt seamless trial designs.